Klona Biotech

Accessible, Scalable, Personalized Implants

Klona Biotech is a company in computational bio based in United Kingdom, founded in 2025.

Profile

Klona Biotech is redefining reconstructive medicine with 3D-printed, personalized implants for mechanically demanding tissues like ligaments, tendons, and cartilage. Millions of patients each year require grafts for these tissues, yet donor shortages and graft failure remain major barriers to recovery. Klona’s proprietary bioprinting platform integrates fiber-reinforced “gel-textile” composites – materials up to twenty times stronger than standard bioprints while remaining compatible with living cells. The result is regenerative implants that combine biological function with real mechanical strength. Founded by Dylan Yeo (University of Oxford) and Thomas Groom (Imperial College London), Klona is developing its first ligament implant and next-generation printer system to enable hospitals to bioprint patient-specific tissues on demand.

Its activity falls under computational bio; the profile below is assembled from public directory data.

The company is recorded as being based in United Kingdom.

It is recorded at the SOSV portfolio company stage.

Recorded headcount: 2-10 employees.

Website: www.klonabiotech.com